- Home
- Products
- Customized ADCs
- C. diff toxin B
- Anti-C. diff toxin B (Bezlotoxumab)-SMCC-DM1 ADC
Anti-C. diff toxin B (Bezlotoxumab)-SMCC-DM1 ADC (CAT#: ADC-W-2060)
This ADC product is comprised of an anti-C. diff toxin B monoclonal antibody conjugated via a SMCC linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, DM1 binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- C. diff toxin B
- Alternative Names
- C. diff toxin B, Clostridium difficile Toxin B
- Overview
- Clostridium difficile Toxin B (tcdB or ToxB) is a glucosyltranferase which is known to innactivate Rho, Cdc42 and Rac within target cells. This toxin is encoded on a pathogenicity region of the C. difficile chromossome and is expressed during the log and stationary phases of growth in response to a variety of environmental stimuli.
- Overview
- Human Anti-C. diff toxin B IgG1-kappa antibody, Bezlotoxumab
- Generic name
- Bezlotoxumab
- Host animal
- Human
- Name
- SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate)
- Description
- Disulfide Linkers, are extensively exploited as a chemically labile linkage. Since the release of disulfide-linked drugs requires a cytoplasmic thiol cofactor, such as glutathione (GSH). Disulfides maintain stable at physiological pH and only when ADCs are internalized inside cells, the cytosol provides reducing environment including intracellular enzyme protein disulfide isomerase, or similar enzymes, drugs can be released.
- Name
- DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
- Description
- Derived from Maytansinoid,a group of cytotoxins structurally similar to rifamycin, geldanamycin, and ansatrienin. The eponymous natural cytotoxic agent maytansine is a 19-member lactam (ansa macrolide) structure originally isolated from the Ethiopian shrub Maytenus ovatus. Maytansinoids can bind to tubulin at or near the vinblastine-binding site, which interfere the formation of microtubules and depolymerize already formed microtubules, inducing mitotic arrest in the intoxicated cells.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-SLC34A2 (Lifastuzumab )-SMCC-DM1 ADC (CAT#: ADC-W-2571)
- Anti-IL6R-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-1446)
- Anti-24P4C12 proteins (clone (Ha5)-1(5)2.1)-VC-MMAE ADC (CAT#: ADC-W-310)
- Anti-CD33 (clone m2H12)-Mc-MMAF ADC (CAT#: ADC-W-114)
- Anti-CD22-SPDB-DM4 ADC (CAT#: ADC-W-2528)
- Anti-CD3E (Catumaxomab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-2274)
- Anti-CA9 (Girentuximab)-SPDB-DM4 ADC (CAT#: ADC-W-741)
- Anti-CEACAM8 (Besilesomab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-2209)
- Anti-Endotoxin (Edobacomab)-MC-MMAF ADC (CAT#: ADC-W-2188)
- Anti-TAG-72 (Satumomab Pendetide)-SMCC-DM1 ADC (CAT#: ADC-W-2156)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-2060. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
CAT# | Product Name | Linker | Payload |
ADC-W-2064 | Anti-C. diff toxin B (Bezlotoxumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
ADC-W-2062 | Anti-C. diff toxin B (Bezlotoxumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
ADC-W-2065 | Anti-C. diff toxin B (Bezlotoxumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
ADC-W-2061 | Anti-C. diff toxin B (Bezlotoxumab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
ADC-W-2063 | Anti-C. diff toxin B (Bezlotoxumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
CAT# | Product Name | Linker | Payload |
ADC-W-473 | Anti-CD37-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-582 | Anti-ERBB2-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-603 | Anti-FOLH1 (clone J591)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-2598 | Anti-GPNMB (Glembatumumab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-496 | Anti-EGFR-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
CAT# | Product Name | Linker | Payload |
ADC-W-2620 | Anti-NCAM1 (Lorvotuzumab )-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-2598 | Anti-GPNMB (Glembatumumab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-2532 | Anti-CD22 (Pinatuzumab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-2560 | Anti-MSLN (Anetumab )-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-2583 | Anti-EGFR (Zalutumumab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.